Evidence accumulated by our group over the last decade suggest that the peripheral immune system (including T lymphocytes and blood-borne monocytes), in concert with the central nervous system (CNS) resident immune cells (microglia)
, play a pivotal role in CNS maintenance, protection and repair [7] [8] [9] [10] [11] [12] [13] . Specifically, it was shown in various models of CNS insults that the outcome of the injury is far more severe in immune deficient mice [14] [15] [16] and that passive transfer of T cells recognizing abundant self-antigens in the brain mitigates the ensuing damage to the CNS [8, 15, [17] [18] [19] [20] . Additionally, in animal models of chronic neurodegenerative diseases, boosting of T-cell levels by active or passive vaccination attenuates disease symptoms and slows down disease progression [21] [22] [23] [24] , in part, by modulating the microglial phenotype and local cytokine profile [22] . [20, 25] , and as a corollary, active vaccination in some strains of ALS mice [26] , or passive transfer of activated T cells, is able to extend life expectancy [24] .
In the mouse model of ALS, it is becoming clear that the ability of the motor neurons to resist the spread of toxicity from the surrounding damaged cells is greatly influenced by the peripheral T cells. Thus for example, breeding mSOD1 mice with immunodeficient mice shortens their life span
We [13, [28] [29] [30] . Although not the primary cause of the disease, this phenomenon might contribute to the lack of recovery and to further exacerbation of the disease conditions. Based on our understanding of the immune system's involvement in CNS maintenance [27, 31] , we suggested that thymic involution might occur in ALS, and could explain the aggressive and rapid progression of the disease due to the insufficient T-cell mediated protection.
have recently proposed a working hypothesis suggesting that in chronic neurological diseases, before their clinical onset, there is a period of equilibrium that involves a competition between the immune system and the disease-inducing factors. The symptomatic disease emerges only when the immune system fails to cope with such locally emerging threatening factors [27]. Such an immune failure could be a reflection of increasing levels of disease-causing factors that exceed the ability of the immune system to contain, or of a situation in which immune function deteriorates concomitantly with disease progression, due to factors indirectly or directly related to the diseasecausing entity. The T-cell population is maintained by thymic release of nascent naïve T cells throughout life. Bone marrow derived T-lymphocyte precursors migrate to the thymus, where they mature and differentiate into functional T lymphocytes. T-cell malfunction can be manifested at several levels: deficiency in memory cells specific to certain antigens, increased levels of regulatory T cells that suppress effector T-cell activity or a decrease in thymic output. Transient or chronic manifestations of thymic involution have been demonstrated in several diseases
Here, we describe a thymic malfunction/defect that appears to develop in parallel to the motor neuron dysfunction, both in a mouse model of ALS, mSOD1 (G93A), and in ALS patients. 
Materials and methods

Animals
FACS analysis of mouse thymocytes and splenocytes
The thymus/spleen was minced and passed through a 40- Table 2 . 
Statistical analysis
The JMP statistics package was used to perform statistical analysis of all data. Data were analysed using a two-tailed Student's t-test or a Wilcoxon-Mann-Whitney test, corrected for a large sample approximation, with genetic background (mice) or clinical status (human) as the between-subject factors.
Results
Thymic malfunction in mSOD1 mice
) cells [34]. T-cell precursors that enter the thymic cortex are DN. As maturation proceeds, cells move toward the medulla and become DP thymocytes. DP cells continue their maturation by reaching the medulla and becoming mature SP T cells; they then leave the thymus to travel through the bloodstream and reach secondary lymphoid organs [34]. To search for a T-cell deficit that may occur in ALS during the course of disease progression, we first analysed the thymic cellular composition in mSOD1 mice (G93A) during disease progession (120-130-day-old animals), as well as in wild-type age-matched controls. We found a significant reduction in thymic cell content during the course of disease progression in mSOD1 mice (Fig. 1A), compared to their agematched wild-type controls. In absolute terms, the thymocyte number in mSOD1 mice was significantly lower in all thymocyte populations tested: DN cells, DP cells, and the two populations of SP cells (Fig. 1B-E). This reduction in thymic cellularity correlated with an increased proportion of DN cells, and decreased proportion of DP cells (Fig. 1F and G, respectively). These results suggested that the thymus of ALS mice undergoes accelerated degeneration. To address whether this phenomenon is correlated with disease progression, we tested thymic cellularity in 60-day-old mSOD1 mice, before disease onset. The only difference found between wild-type and mSOD1 mice at this time-point was the elevation in the number of CD8
ϩ thymocytes (Fig. 1H) . By disease end-stage, the shrinkage of the thymus in the mSOD1 mice could be observed macroscopically (Fig. 1I) Fig. 2A) . Moreover, plotting the sjTREC levels as a function of age (Fig. 2B) (Fig. S1) . Fig. 3A and B) . (Fig. 1J) [44] . The [45] . The ␥-chain gene, although typically not expressed on the cell surface, remains rearranged in the T-cell genome, and provides a conventional marker of clonality due to its expression in both TCR␣␤ and TCR␥␦ T-cells [46] [47] [48] . We therefore evaluated the peripheral TCR␥ repertoire in ALS patients. We found that the repertoire of the existing T-cell population in these patients was restricted (Fig. 4) , although the repertoire did not constitute a monoclonal population, as found in cancer [48] .
Thymic output deficit in ALS patients
MRI and one by X-ray. In all tested patients no traces of thymus tissue could be detected. An axial double inversion recovery image at the level of the ascending aorta in the examined ALS patients (males, 30 and 40 years old) showed clear retrosternal fat with no evidence of thymic remnants
The TCR is created through a series of sequential recombination events between the different TCR genes (TCRD Ͼ TCRG Ͼ TCRB Ͼ TCRA) as well as within each specific gene (e.g. TCRD: D␦2-D␦3, D␦2-J␦1, V␦-J␦1); different segments are excised during each stage of this sequential process [32, 41]. To further characterize thymic function in ALS patients, we measured the levels of two additional recombination events of TCRD, D␦2-D␦3 (D-D) and D␦2-J␦1 (D-J), which represent the early and late DN stage, respectively [32], and occur prior to the exclusion of the sjTRECs. QPCR results were normalized against TCRA germline DNA (an indication of T-cell number). No difference was found between ALS patients and healthy donors in the two events tested, the D-D (t21 ϭ Ϫ0.15; P ϭ 0.88) and D-J (t21 ϭ Ϫ0.35; P ϭ 0.73) recombinations (
Because most T-cell recombination events occur at the transition stage between DN and DP progenitors [32], our results from patients are consistent with the increased proportion of DN thymocytes and decreased proportion of DP thymocytes in the thymus of mSOD1 mice (Fig. 1F and G), and the loss of thymic architecture in terms of a distinct cortex and medulla
TCR repertoire is comprised of naïve T cells that have recently migrated from the thymus, as well as a circulating pool of antigen-experienced peripheral T cells. Lymphoid clonality is often detected by PCR analysis of TCR␥ gene rearrangement, which represents the 'prototype' of restricted-repertoire targets
Changes in expression of immune-related genes in ALS patients relative to age-matched controls
In order to better understand the global immune deviation associated with ALS, the expression profile of 96 immune-related genes was studied using a predesigned array (TLDA) (Fig. 5A-E 
), relative to the healthy controls, the patients showed a dramatic reduction in all of the above genes, all of which are key factors in the T-cell mediated immune response. Thus for example, IL-8 is a major chemoattractant that signals immune cells to arrive to the site of need, in the initiation of an immune response [49]. CD80 and CD86 are the most important T-cell co-stimulatory molecules required for activation of the T cells [50]. Consistent with this trend is the observed reduction in the expression of IL18 and IFNG; IL-18 is a pleiotropic cytokine involved in the polarization of the T-cell response and induces production of interferon (IFN)-␥, which is one of the major cytokines associated with CD4
ϩ T cells [51] . (Fig. 5F) 
To gain a molecular insight to the peripheral immune deficit in the ALS patients, we also compared in the mRNA of PBMCs from these patients the expression ratio of BAX to BCL2, which determines the susceptibility of a cell to apoptosis. We found a significant increase in the BAX to BCL2 ratio in ALS patients
Discussion
In this study, we present novel data demonstrating thymic malfunction in both a mouse model of ALS and in ALS patients. [12, 52, 53] 
reduction in two earlier events of TCR rearrangement (D-D and D-J). Moreover, in ALS patients, we demonstrate restricted T-cell clonality. Gene array revealed a significant reduction in expression of genes associated with T-cell activity, including CD80, CD86, IL18 and IFNG. The loss of T cells in the patients was also associated with a reduction in expression of the antiapoptotic gene, BCL2, and the complete disappearance of the thymus tested by imaging in three young patients. The scarcity of blood-borne immune cells in healthy CNS parenchyma, in combination with the concept of the CNS being an 'immune privileged site', have contributed to the common view that, under normal conditions, the CNS functions most effectively in the absence of any immune cell activity. However, it recently became evident that the nervous and immune systems engage in an intense bidirectional dialogue. For example, immune cells (peripheral T cells and resident microglia) and immune-related molecules (Toll-like receptors) were found to have a role in the different steps of neurogenesis, including progenitor cell proliferation and neuronal differentiation
. In the injured CNS, immune cells (infiltrating monocyte-derived macrophages and peripheral CD4
ϩ T cells) contribute to recovery and regulation of neurotoxicity by secretion of growth factors, removal of dying neurons and detoxification of the environment [52, [54] [55] [56] [57] . In line with these findings, boosting of T-cell levels was shown to be beneficial in animal models of acute or chronic neurodegenerative disorders [8, 17, 24] . astrocytes [20, 24, 25] [75] , higher rates of retroviral enzymes detected in the blood [76, 77] and a higher frequency of systemic mycoplasmal infections [78] . Moreover, the AIDS virus was shown to cause a form of ALS-like disease [79] .
We show in the present study that the malfunctioning of the thymus in ALS patients is manifested by a combination of several parameters: reduced levels of sjTRECs, (with no changes in levels of early T-cell recombination events), restricted T-cell polyclonality and disappearance of thymic tissue. In addition, a reduction in the potential activity of the remaining T cells was demonstrated by the reduced expression of the genes encoding two key co-stimulatory molecules, CD80 and CD86, and two cytokines, Reduction in sjTREC levels has also been observed in autoimmune diseases [80] , cancer [81] , aging and HIV infection [13] . Yet, the finding in the present study of a reduction in sjTRECs together with normal levels of the early T-cell recombination events differs from the profile observed in any other pathology investigated, such as cancer [41] . Importantly, reduced levels of naïve T-cells also characterize thymic aging [82] , autoimmune diseases [82] and early stages of HIV [83] . An overall reduction in all T-cell subsets, on the other hand, characterizes immunodeficiency states, such as the late stage of HIV [84] .
In 
